

Press release
6 March 2026

Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade

Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) issued a convertible loan note to Fenja Capital II A/S (“Fenja Capital”) on 29 December 2025, with a nominal amount of DKK 25 million. Fenja Capital has now exercised its right to partially convert the convertible loan, whereby a total of 429,363 new ordinary shares has been issued at a conversion price of DKK 9,975 per share, corresponding to a nominal value of approximately DKK 4.3 million. In connection with the conversion, all of the converted shares have been sold by Fenja Capital in a block transaction executed between Fenja Capital and a consortium of long-term investors at a price of DKK 15.75.

As a result of the conversion, the number of ordinary shares in Curasight will increase by 429,363, which results in the total number of outstanding shares in the Company increases from 47,922,841 shares to 48,352,204 shares. The share capital increases with DKK 21,468.15 from DKK 2,396,142.05 to DKK 2,417,610.20. This corresponds to a dilution effect of approximately 0.9 percent of the total number of ordinary shares in the company after the conversion.

“We see it as positive that Fenja Capital has decided to convert into shares, as this reduces Curasight’s debt and extends our financial runway,” says Curasight CEO Ulrich Krasilnikoff.

In connection with the conversion, all of the converted shares have been sold by Fenja Capital in a block transaction executed between Fenja Capital and a consortium of long-term investors at a price of DKK 15.75, corresponding to a total transaction value of approximately DKK 6.8 million. The subscription price represents a discount of approximately 0.9 percent to today’s closing price of the Company’s share on Spotlight Stock Market.

About Curasight A/S

Curasight is advancing uTREAT[®], a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT[®] targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors.

The company's theranostic platform also includes uTRACE[®], a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT[®]. uTRACE[®] supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications.

The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen

Bookrunner

Sedermera Corporate Finance AB has acted as sole bookrunner in connection with the placement.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
www.curasight.com